Post-SSRI Syndrome (PSSD) is a condition where debilitating symptoms persist - or even emerge - after stopping serotonergic meds like SSRIs or SNRIs. Though these drugs treat depression/anxiety, a subset of patients paradoxically worsen. Alarmingly, adverse responses can endure long after treatment ends. Individual genetics - rarely considered when prescribing - likely explain this divergence in outcomes. For instance, the 5-HT1A receptor (a primary SSRI target) is vital for cognition and hypothalamic hormone regulation, yet its expression varies widely due to polymorphisms. Single-nucleotide polymorphisms (SNPs) - simple “letter” swaps in our DNA - can dramatically alter health outcomes. In one study of 200 men on SSRIs, a single SNP tripled the risk of sexual side effects. These enduring sexual issues form the core of PSSD. Sexual dysfunction may begin during SSRI use and often persists for years after cessation. One analysis found 60% of males and 57% of females developed sexual dysfunction after 8 weeks on paroxetine, sertraline, or fluoxetine. A larger study of 1,000+ patients estimated rates up to 70%. For references and more, read here: secondlifeguide.com/pssd-2/

@PAS_secondlife any new info on PFS?